%0 Journal Article
%T Discovery of 2-phenylquinazolines as potent Mycobacterium avium efflux pump inhibitors able to synergize with clarithromycin against clinical isolate.
%A Cernicchi G
%A Rampacci E
%A Massari S
%A Manfroni G
%A Barreca ML
%A Tabarrini O
%A Cecchetti V
%A Felicetti T
%A Di Luca M
%A Poma NV
%A Tavanti A
%A Passamonti F
%A Rindi L
%A Sabatini S
%J Arch Pharm (Weinheim)
%V 0
%N 0
%D 2024 Jun 26
%M 38923553
%F 4.613
%R 10.1002/ardp.202400296
%X Nontuberculous mycobacteria (NTM), which include the Mycobacterium avium complex, are classified as difficult-to-treat pathogens due to their ability to quickly develop drug resistance against the most common antibiotics used to treat NTM infections. The overexpression of efflux pumps (EPs) was demonstrated to be a key mechanism of clarithromycin (CLA) resistance in NTM. Therefore, in this work, 24 compounds from an in-house library, characterized by chemical diversity, were tested as potential NTM EP inhibitors (EPIs) against Mycobacterium smegmatis mc2 155 and M. avium clinical isolates. Based on the acquired results, 12 novel analogs of the best derivatives 1b and 7b were designed and synthesized to improve the NTM EP inhibition activity. Among the second set of compounds, 13b emerged as the most potent NTM EPI. At a concentration of 4 µg/mL, it reduced the CLA minimum inhibitory concentration by 16-fold against the clinical isolate M. avium 2373 overexpressing EPs as primary mechanism of CLA resistance.